Compare Becton Dickinson and Co (BDX) vs iShares 7-10 Year Treasury Bond ETF (IEF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs iShares 7-10 Year Treasury Bond ETF — how do they compare? Becton Dickinson and Co trades at $154.29 (market cap $41.51B), while iShares 7-10 Year Treasury Bond ETF trades at $93.41. The key difference: Becton Dickinson and Co pays a 2.79% dividend while iShares 7-10 Year Treasury Bond ETF pays none, and Becton Dickinson and Co is trading nearer its 52-week high, iShares 7-10 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| BDX | IEF | |
|---|---|---|
Market Cap | $41.51B | — |
Sector | Health | — |
52-Week High | $185.39 | $97.99 |
52-Week Low | $135.49 | $93.11 |
Enterprise Value | $57.97B | — |
Dividend Yield | 2.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $153.83, up 1.24% today, with technical indicators showing a neutral to bullish bias. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.90 exceeding expectations. Revenue growth remains steady, reaching $21.84B in 2025, though net margins have compressed to 5.12%. Recent news highlights BDX's innovation in medical technology and positive analyst sentiment.
The outlook for BDX appears balanced. Upside potential exists from continued earnings beats and strategic positioning in growing healthcare segments like GLP-1 drug support equipment. However, risks include margin pressure, elevated debt levels, and cautious hospital spending. The consensus price target of $173.40 suggests moderate upside from current levels.
IEF trades at $93.29, down 0.36% on the day, with a bearish technical signal driven by moving averages. The ETF shows neutral oscillators but oversold short-term RSI. Recent news highlights bond ETF inflows and investor focus on yield amid Federal Reserve uncertainty, with articles from Benzinga (July 14, 2026) and CNBC (June 25, 2026) noting record flows and rate hike speculation.
Outlook remains cautious due to interest rate sensitivity and macroeconomic pressures. Risks include potential Fed hikes and inflation concerns, but the oversold RSI may offer short-term support. Investors should weigh yield attractiveness against duration risk in the current rate environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About iShares 7-10 Year Treasury Bond ETF
The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity of greater than or equal to seven years and less than ten years. The fund will invest at least 80% of its assets in the component securities of the underlying index, and the fund will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index.
Read more on IEF →
